Ovid Therapeutics Inc.
OVIDAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 15, 2026 | Wolfe Research | $5.00(+128%) | $2.19 | TheFly | |
| Oct 5, 2026 | Guggenheim | $7.00(+199%) | $2.34 | TheFly | |
| Sep 11, 2026 | H.C. Wainwright | Raghuram Selvaraju | $5.00(+90%) | $2.63 | TheFly |
| Sep 3, 2026 | Roth Capital | Boobalan Pachaiyappan | $8.00(+186%) | $2.79 | TheFly |
| May 14, 2026 | Roth Capital | $7.00(+148%) | $2.82 | TheFly | |
| Apr 9, 2026 | H.C. Wainwright | $4.00(+39%) | $2.88 | TheFly | |
| Dec 11, 2025 | Roth Capital | Boobalan Pachaiyappan | $3.00(+85%) | $1.63 | TheFly |
| Nov 24, 2025 | H.C. Wainwright | $2.00(+43%) | $1.40 | TheFly | |
| Jul 2, 2024 | H.C. Wainwright | Raghuram Selvaraju | $3.00(+248%) | $0.86 | StreetInsider |
| May 20, 2024 | BTIG | Thomas Shrader | $11.00(+250%) | $3.14 | StreetInsider |
| May 14, 2024 | Oppenheimer | Francois Brisebois | $8.00(+148%) | $3.23 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Sep 11, 2026 |
| Oppenheimer | maintain | Outperform | Aug 3, 2026 |
| Wedbush | maintain | Outperform | Apr 15, 2026 |
| HC Wainwright & Co. | maintain | Buy | Apr 9, 2026 |
| BTIG | maintain | Buy | Mar 26, 2026 |
| Wedbush | maintain | Outperform | Mar 20, 2026 |
| HC Wainwright & Co. | maintain | Buy | Dec 22, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 24, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 27, 2025 |
| BTIG | maintain | Buy | Mar 24, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 24, 2025 |
| Wedbush | maintain | Outperform | Mar 12, 2025 |
| Oppenheimer | upgrade | Perform →Outperform | Jan 29, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 4, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 30, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 19, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jul 26, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jul 2, 2024 |
| B. Riley Securities | maintain | Buy | Jun 18, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 18, 2024 |
| BTIG | maintain | Buy | Jun 18, 2024 |
| Citigroup | maintain | Neutral | Jun 18, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 16, 2024 |
| Citigroup | maintain | Neutral | May 7, 2024 |
| Ladenburg Thalmann | maintain | Buy | May 2, 2023 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-0.08| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.08 | $-0.12 | $733.0K | $21.4K |
| May 12, 2026 | $-0.12 | $-0.12 | — | $56.7K |
| Mar 18, 2026 | $0.06 | $-0.10 | $718.0K | $78.3K |
| Nov 12, 2025 | $-0.17 | $-0.15 | $132.0K | $62.6K |
| Aug 13, 2025 | $-0.06 | $-0.16 | $6.3M | $61.3K |
| May 13, 2025 | $-0.14 | $-0.14 | $130.0K | $42.5K |
| Mar 11, 2025 | $-0.13 | $-0.16 | $76.0K | $100.0K |
| Nov 12, 2024 | $-0.20 | $-0.19 | $173.0K | $187.5K |
News
Ono Pharmaceutical (OTCMKTS:OPHLF - Get Free Report) and Ovid Therapeutics (NASDAQ: OVID - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk. Volatility and Risk Ono Pharmaceutical has a beta
NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company's management will participate in three upcoming investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference – Tuesday, November 10 at 8:30 am ET Stifel 2026 Healthcare Conference – Wednesday, November 11 at 3:20 pm ET UBS European Healthcar…
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment of Matt David, M.D., as Chief Financial Officer.
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company's management will participate in two upcoming investor conferences: Cantor Global Healthcare Conference – Wednesday, September 9 at 2:10 pm ET H.C.
BlackRock Inc. bought a new position in shares of Ovid Therapeutics (NASDAQ: OVID) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 10,823,480 shares of the company's stock, valued at approximately $29,115,000. BlackRock Inc. owned 5.80% of Ovid Therapeutics
Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.06 per share a year ago.
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including financial results for the second quarter ended June 30, 2026.